Barrington analyst Michael Petusky raised the firm’s price target on Orthofix (OFIX) to $17 from $16 and keeps an Outperform rating on the shares. The company reported strong Q2 results and affirmed its fiscal 2025 outlook, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OFIX: